1. Home
  2. SVV vs DMRA Comparison

SVV vs DMRA Comparison

Compare SVV & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

HOLD

Current Price

$9.48

Market Cap

1.4B

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$22.33

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SVV
DMRA
Founded
1954
2011
Country
United States
United States
Employees
N/A
7
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SVV
DMRA
Price
$9.48
$22.33
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$13.67
$43.00
AVG Volume (30 Days)
1.3M
329.5K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,678,954,000.00
N/A
Revenue This Year
$6.91
N/A
Revenue Next Year
$7.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.19
N/A
52 Week Low
$6.91
$16.50
52 Week High
$13.89
$28.76

Technical Indicators

Market Signals
Indicator
SVV
DMRA
Relative Strength Index (RSI) 68.78 37.71
Support Level $9.03 $16.50
Resistance Level $9.98 $26.66
Average True Range (ATR) 0.41 1.44
MACD 0.20 -0.18
Stochastic Oscillator 99.43 7.82

Price Performance

Historical Comparison
SVV
DMRA

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: